Jenkem Technology Co

Jenkem Technology Co Forward P/E

The Forward P/E Ratio of Jenkem Technology Co (688356.SS) as of Nov 18, 2026 is 93.76. In the previous year, Forward P/E Ratio was 199.20 — a change of -52.93% (lower).

Forward P/E

93.76

YoY

-52.93%

Last updated:

Forward P/E Ratio of Jenkem Technology Co is 2025 93.76 . Forward P/E Ratio of Jenkem Technology Co was 2024 199.20 . It decreases by -52.93% lower compared to the previous year.

The Jenkem Technology Co Forward P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Forward P/E
Date
Forward P/E
Jan 1, 2018
163.88 CNY
Jan 1, 2019
96.58 CNY
Jan 1, 2020
69.37 CNY
Jan 1, 2021
33.81 CNY
Jan 1, 2022
31.81 CNY
Jan 1, 2023
51.35 CNY
Jan 1, 2024
199.20 CNY
Jan 1, 2025
93.76 CNY
The Jenkem Technology Co Forward P/E history
YEARForward P/EYoY
93.76-52.93%
199.20+287.91%
51.35+61.42%
31.81-5.92%
33.81-51.26%
69.37-28.17%
96.58-41.07%
163.88-41.63%
280.74-81.17%
1,490.71—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Jenkem Technology Co Stock analysis

What does Jenkem Technology Co do? Jenkem Technology Co., Ltd. generates revenue through the research, development, production, and sales of medical polyethylene glycol (PEG) and its active derivatives. The company's primary products are sold to pharmaceutical companies, research institutions, and medical device manufacturers that use these materials in drug development and production. Technical services such as patent and non-patent technology licensing, as well as R&D services, also contribute to the company's income. The firm's customer segments include entities involved in drug research, development, and production, as well as scientific research organizations. The company's business model focuses on providing specialized materials and technical support for the medical and pharmaceutical sectors. Medical polyethylene glycol and its active derivatives serve as critical components in various medical applications, driving demand from industry partners. By offering both physical products and intellectual property services, Jenkem Technology diversifies its revenue streams within the healthcare technology space. Jenkem Technology Co., Ltd. operates with a clear focus on the medical and pharmaceutical industries, targeting clients that require high-quality PEG-based materials for their research and manufacturing processes. The company's technical services, including licensing and R&D support, further strengthen its position as a supplier of essential materials and solutions in the healthcare sector. Jenkem Technology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Jenkem Technology Co stock

Forward P/E Ratio of Jenkem Technology Co is 93.76 in 2025.

Forward P/E Ratio of Jenkem Technology Co changed from 199.20 to 93.76, representing a -52.93% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio Jenkem Technology Co since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's Jenkem Technology Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Jenkem Technology Co

All Key Metrics — Jenkem Technology Co